Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing. Click here ...

First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

People with type 2 diabetes don’t make an adequate amount of insulin to manage their blood sugar. Stem cell therapy may ...

Thalassaemia patients in Karnataka face hope and hardship, battling disease with silent strength and financial struggles.

Two robust clinical datasets from CB-010 and CB-011 expected to be disclosed in H2 2025 -- -- $212.5 million in cash, cash equivalents, and marketable securities expected to fund the Company’s current ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid ...

NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...